ClinicalTrials.gg
CompletedNCT014127364563-003Updated Dec 23, 2014

A Phase IIa Study of KHK4563

A Phase 2 interventional study of KHK4563 and KHK4563 in Uncontrolled and Suspected Eosinophilic Asthma, sponsored by Kyowa Kirin Co., Ltd.. Completed at 29 sites in 2 countries. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-12-23.

Sponsored by Kyowa Kirin Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies testing benralizumab in Asthma — 3 open to participants now, 4 under way, 2 of them phase 3. benralizumab · Asthma.

Enrollment
24th of 39
106 · median 128
Started
2011
the only one that year
Phase 2
7 of 39
none open now
Registered
6th of 39
by date
Lead sponsor
1 of 39
Kyowa Kirin Co., Ltd.

Among the 39 studies testing benralizumab in Asthma, this one is the 24th largest by enrollment, is the only one that started in 2011, is one of 7 in phase 2, and was the 6th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

3 of the 39 studies testing benralizumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About benralizumab

benralizumab: first FDA approval 2017 (FASENRA), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies testing benralizumab in Asthma, or all of them as a file.
02

Study summary

This is a double-blind, placebo-controlled dose-ranging study of KHK4563 to evaluate the effect of multiple-dose subcutaneous administration of KHK4563 on the annual asthma exacerbation rate in adult subjects with uncontrolled, suspected eosinophilic asthma.

03

Conditions studied

  • Uncontrolled and Suspected Eosinophilic Asthma

Browse trials for

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 20 through 75 years at the time of Week -3 visit.
  2. Written obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.
  3. Physician prescribed daily use of medium-dose or high-dose ICS plus LABA or any combination of sequential dosing of either medium-dose or high-dose ICS/LABA for at least 12 months prior to Week -3 visit. Dose must be stable for at least 30 days prior to Week -3 visit.
  4. At least 2, but not more than 6, documented asthma exacerbations in the 12 months prior to Week -3 visit that required use of a systemic burst.

Exclusion criteria

Exclusion Criteria

  1. Any condition (eg, any eosinophilic lower respiratory disease other than asthma, Churg-Strauss syndrome, hypereosinophilic syndrome, eosinophilic bronchitis, eosinophilic pneumonia, (COPD), bronchiectasis or cystic fibrosis (CF)) that, in the opinion of the investigator or Medical Expert, would interfere with evaluation of the product or interpretation of subject safety or study results.
  2. Any abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during screening period, which in the opinion of the investigator, may put the subject at risk because of his/her participation in the study, or may influence the results of the study, or the subject's ability to participate in the study.
  3. Acute upper or lower respiratory infections requiring antibiotics or antiviral medications within 30 days prior to Week -3 visit or during the screening period.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    2mg

    sterile lyophilized formulation, 2mg

    Drug: KHK4563

  • Experimental
    20mg

    sterile lyophilized formulation, 20mg

    Drug: KHK4563

  • Experimental
    100mg

    sterile lyophilized formulation, 100mg

    Drug: KHK4563

  • Placebo comparator
    Placebo

    two SC administration on day 1

    Drug: Placebo

Interventions

  • every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.

  • every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.

  • every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.

  • DrugPlacebo

    every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.

06

What researchers measure

Primary outcomes

  1. evaluation of the effect of multiple-dose subcutaneous(SC) administration of benralizumab on the annual asthma exacerbation rate in adult subjects with uncontrolled, suspected eosinophilic asthma.

    annual asthma exacerbation rate

    Time frame: Immediately following the first administration of study drug through Study Week 52.

Secondary outcomes

  1. Pulmonary function as assessed by Forced Expiratory Volume in 1 Second (FEV1) and Peak Expiratory flow (PEF)

    Pre-dose/pre-bronchodilator Forced Expiratory Volume in 1 Second ( FEV1 ) at the study centre, morning and evening peak expiratory flow (PEF)

    Time frame: From first administration of study drug through Study Week 52.

  2. Asthma control as assessed by ASTHMA CONTROL QUESTIONNAIRE6(ACQ6)

    ASTHMA CONTROL QUESTIONNAIRE6(ACQ6)

    Time frame: From first administration of study drug through Study Week 52.

  3. Number of participants with Adverse Events as a Measure of Safety and Tolerability

    Adverse Events/Serious Adverse Events (AE/SAE) - Laboratory variables - ECG (Electrocardiogram) - Physical Examination

    Time frame: From first administration of study drug through Study Week 68.

  4. Time Profiles of Serum Concentration

    Serum benralizumab concentration

    Time frame: From first administration of study drug through Study Week 68

  5. Immunogenicity by serum incidence rate of positive anti-drug antibody

    Anti-drug antibodies (ADA)

    Time frame: From first administration of study drug through Study Week 68

07

Study locations

29 sites
  • Nagoya-shi, Aichi, Japan
  • Toyota-shi, Aichi, Japan
  • Kamogawa-shi, Chiba, Japan
  • Fukuoka-shi, Fukuoka, Japan
  • Ogaki-shi, Gifu, Japan
  • Hiroshima-shi, Hiroshima, Japan
  • Sapporo-shi, Hokkaido, Japan
  • Himeji-shi, Hyogo, Japan
  • Kobe-shi, Hyogo, Japan
  • Sagamihara-shi, Kanagawa, Japan
  • Yokohama-shi, Kanagawa, Japan
  • Kumamoto-shi, Kumamoto, Japan
  • Kyoto-shi, Kyoto, Japan
  • Nagasaki-shi, Nagasaki, Japan
  • Kishiwada-shi, Osaka, Japan
  • Koshigaya-shi, Saitama, Japan
  • Shizuoka-shi, Shizuoka, Japan
  • Itabashi-ku, Tokyo, Japan
  • Shinagawa-ku, Tokyo, Japan
  • Shinjuku-ku, Tokyo, Japan
  • Mizunami-shi, Japan
  • Osakasayama-shi, Japan
  • Oura-gun, Japan
  • Seto-shi, Japan
  • Chungcheongbuk-do, Korea, Republic of
  • Gwangju, Korea, Republic of
  • Gyenggi-do, Korea, Republic of
  • Seoul, Korea, Republic of
  • Suwon-si, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2011, a primary completion of Jul 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2011
First posted
Aug 9, 2011
Start
Aug 2011
Primary completionActual
Jul 2013
CompletionActual
Oct 2013
Last update
Dec 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01412736
Responsible party
Sponsor
First posted
Aug 9, 2011
Start date
Aug 2011
Primary completion
Jul 2013
Completion
Oct 2013
Last update
Dec 23, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion